118 related articles for article (PubMed ID: 8008704)
21. Absorption characteristics of model compounds with different molecular weights from the serosal caecal surface in rats.
Nishida K; Nose S; Kuma A; Mukai T; Kawakami S; Nakashima M; Sasaki H; Sakaeda T; Nakamura J
J Pharm Pharmacol; 2002 Jul; 54(7):1005-9. PubMed ID: 12162704
[TBL] [Abstract][Full Text] [Related]
22. Absorption of phenolsulfonphthalein as a model across the mesenteric surface in rats to determine the drug absorption route after intraperitoneal administration.
Nishida K; Nose S; Kuma A; Mukai T; Nakashima M; Sasaki H; Nakamura J
J Pharm Pharmacol; 2004 May; 56(5):683-7. PubMed ID: 15142348
[TBL] [Abstract][Full Text] [Related]
23. Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes.
Lindmark T; Schipper N; Lazorová L; de Boer AG; Artursson P
J Drug Target; 1998; 5(3):215-23. PubMed ID: 9606011
[TBL] [Abstract][Full Text] [Related]
24. Absorption characteristics of compounds with different molecular weights after application to the unilateral kidney surface in rats.
Nishida K; Tomiyama N; Mukai T; Nakashima M; Sasaki H; Nakamura J
Eur J Pharm Biopharm; 2004 Nov; 58(3):705-11. PubMed ID: 15451548
[TBL] [Abstract][Full Text] [Related]
25. Absorption-enhancing effects of sodium caprate and palmitoyl carnitine in rat and human colons.
Shimazaki T; Tomita M; Sadahiro S; Hayashi M; Awazu S
Dig Dis Sci; 1998 Mar; 43(3):641-5. PubMed ID: 9539662
[TBL] [Abstract][Full Text] [Related]
26. Effect of selective cyclooxygenase-2 inhibitor lumiracoxib on phenolsulfonphthalein disposition in rats.
Honjo H; Uwai Y; Nabekura T
Drug Metabol Drug Interact; 2014; 29(3):203-6. PubMed ID: 24870608
[TBL] [Abstract][Full Text] [Related]
27. Estimation of absorption enhancement by medium-chain fatty acids in rat large intestine.
Higaki K; Yata T; Sone M; Ogawara K; Kimura T
Res Commun Mol Pathol Pharmacol; 2001; 109(3-4):231-40. PubMed ID: 11758652
[TBL] [Abstract][Full Text] [Related]
28. Does bacitracin have an absorption-enhancing effect in the intestine?
Gotoh S; Nakamura R; Nishiyama M; Fujita T; Yamamoto A; Muranishi S
Biol Pharm Bull; 1995 May; 18(5):794-6. PubMed ID: 7493005
[TBL] [Abstract][Full Text] [Related]
29. Promotion of rectal absorption of sodium ampicillin by disodium glycyrrhetinic acid 3 beta-O-monohemiphthalate in rats.
Mishima M; Nagatomi A; Yamakita T; Miura Y; Tsuzuki O
Biol Pharm Bull; 1995 Apr; 18(4):566-70. PubMed ID: 7655429
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo preclinical evaluation of a minisphere emulsion-based formulation (SmPill®) of salmon calcitonin.
Aguirre TA; Rosa M; Coulter IS; Brayden DJ
Eur J Pharm Sci; 2015 Nov; 79():102-11. PubMed ID: 26349051
[TBL] [Abstract][Full Text] [Related]
31. Absorption characteristics of model compounds from the small intestinal serosal surface and a comparison with other organ surfaces.
Nishida K; Kuma A; Fumoto S; Nakashima M; Sasaki H; Nakamura J
J Pharm Pharmacol; 2005 Aug; 57(8):1073-7. PubMed ID: 16102265
[TBL] [Abstract][Full Text] [Related]
32. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D-maltopyranoside.
Uchiyama T; Sugiyama T; Quan YS; Kotani A; Okada N; Fujita T; Muranishi S; Yamamoto A
J Pharm Pharmacol; 1999 Nov; 51(11):1241-50. PubMed ID: 10632081
[TBL] [Abstract][Full Text] [Related]
33. Site-dependent effect of aprotinin, sodium caprate, Na2EDTA and sodium glycocholate on intestinal absorption of insulin.
Morishita M; Morishita I; Takayama K; Machida Y; Nagai T
Biol Pharm Bull; 1993 Jan; 16(1):68-72. PubMed ID: 7690292
[TBL] [Abstract][Full Text] [Related]
34. Effect of medium-chain glycerides on the intestinal absorption of phenol red: studies on mechanisms of the promoting effect.
Higaki K; Takechi N; Kato M; Hashida M; Sezaki H
J Pharm Sci; 1990 Apr; 79(4):334-8. PubMed ID: 2352146
[TBL] [Abstract][Full Text] [Related]
35. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells.
Lindmark T; Kimura Y; Artursson P
J Pharmacol Exp Ther; 1998 Jan; 284(1):362-9. PubMed ID: 9435199
[TBL] [Abstract][Full Text] [Related]
36. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of intestinal absorption enhancement and local mucosal toxicity of two promoters. I. Studies in isolated rat and human colonic mucosae.
Maher S; Kennelly R; Bzik VA; Baird AW; Wang X; Winter D; Brayden DJ
Eur J Pharm Sci; 2009 Nov; 38(4):291-300. PubMed ID: 19737613
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies.
Maher S; Wang X; Bzik V; McClean S; Brayden DJ
Eur J Pharm Sci; 2009 Nov; 38(4):301-11. PubMed ID: 19664704
[TBL] [Abstract][Full Text] [Related]
39. Delivery advantage to the unilateral kidney by direct drug application to the kidney surface in rats and pharmacokinetic verification based on a physiological model.
Nishida K; Kamenosono M; Kuma A; Fumoto S; Mukai T; Nakashima M; Sasaki H; Nakamura J
J Drug Target; 2005 May; 13(4):215-23. PubMed ID: 16051533
[TBL] [Abstract][Full Text] [Related]
40. Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport.
Dahlgren D; Roos C; Lundqvist A; Tannergren C; Sjöblom M; Sjögren E; Lennernäs H
Int J Pharm; 2018 Oct; 549(1-2):239-248. PubMed ID: 30055302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
